CD19 and autoimmune hemolytic anemia: Preliminary data from a median 6.8-month follow-up were recently reported in five patients treated with compassionate-use CD19 CAR-T therapy and three enrolled in a Phase 1 trial (NCT06231368) for refractory AIHA (109).